Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 4,173 shares of Cryoport stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $4.88, for a total transaction of $20,364.24. Following the transaction, the chief executive officer now directly owns 740,019 shares in the company, valued at $3,611,292.72. This represents a 0.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Cryoport Price Performance
Shares of NASDAQ:CYRX traded up $1.95 during midday trading on Tuesday, reaching $6.65. 1,518,068 shares of the company's stock traded hands, compared to its average volume of 538,015. The company has a market cap of $328.72 million, a P/E ratio of -1.97 and a beta of 1.67. The company has a fifty day simple moving average of $7.19 and a two-hundred day simple moving average of $7.54. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $20.11.
Cryoport (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $59.53 million for the quarter, compared to analysts' expectations of $58.71 million. During the same quarter in the previous year, the business posted ($0.29) EPS. Equities analysts predict that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on CYRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim began coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a "buy" rating and a $11.00 price target for the company. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $12.29.
Get Our Latest Research Report on CYRX
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Quest Partners LLC grew its stake in Cryoport by 168.5% during the 3rd quarter. Quest Partners LLC now owns 29,083 shares of the company's stock worth $236,000 after buying an additional 18,252 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Cryoport in the third quarter valued at $326,000. Intech Investment Management LLC purchased a new stake in Cryoport in the 3rd quarter worth approximately $105,000. Charles Schwab Investment Management Inc. grew its holdings in Cryoport by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company's stock valued at $3,144,000 after buying an additional 2,226 shares during the period. Finally, Algert Global LLC grew its stake in shares of Cryoport by 282.7% during the 3rd quarter. Algert Global LLC now owns 247,483 shares of the company's stock valued at $2,007,000 after buying an additional 182,808 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.
Cryoport Company Profile
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
